Šárka Pavlová, Ph.D.

Publications that are part of the Web of Science database, possibly also other publications chosen by authors.

2020

• Jaskova, Z; Pavlova, S; Malcikova, J; Brychtova, Y; Trbusek, M, 2020: PRIMA-1(MET) cytotoxic effect correlates with p53 protein reduction in TP53-mutated chronic lymphocytic leukemia cells. LEUKEMIA RESEARCH 89, doi: 10.1016/j.leukres.2019.106288
• Malcikova, J; Pavlova, S; Vonkova, B; Kotaskova, J; Radova, L; Plevova, K; Zenatova, M; Hynst, J; Dvorackova, B; Panovska, A; Brychtova, Y; Tichy, B; Navrkalova, V; Pal, K; Mayer, J; Doubek, M; Pospisilova, S, 2020: Minor-clone TP53 mutations in CLL patients entering first-line treatment: clonal evolution and clinical impact. LEUKEMIA & LYMPHOMA 61, p. 222 - 224

2019

• Spunarova, M; Tom, N; Pavlova, S; Mraz, M; Brychtova, Y; Doubek, M; Panovska, A; Francova, HS; Brzobohata, A; Pospisilova, S; Mayer, J; Trbusek, M, 2019: Impact of gene mutations and chromosomal aberrations on progression-free survival in chronic lymphocytic leukemia patients treated with front-line chemoimmunotherapy: Clinical practice experience. LEUKEMIA RESEARCH 81, p. 75 - 81, doi: 10.1016/j.leukres.2019.04.015

2018

• Janovska, P; Verner, J; Kohoutek, J; Bryjova, L; Gregorova, M; Dzimkova, M; Skabrahova, H; Radaszkiewicz, T; Ovesna, P; Blanarova, OV; Nemcova, T; Hoferova, Z; Vasickova, K; Smyckova, L; Egle, A; Pavlova, S; Poppova, L; Plevova, K; Pospisilova, S; Bryja, V, 2018: Casein kinase 1 is a therapeutic target in chronic lymphocytic leukemia. BLOOD 131(11), p. 1206 - 1218, doi: 10.1182/blood-2017-05-786947
• Plesingerova, H; Janovska, P; Mishra, A; Smyckova, L; Poppova, L; Libra, A; Plevova, K; Ovesna, P; Radova, L; Doubek, M; Pavlova, S; Pospisilova, S; Bryja, V, 2018: Expression of COBLL1 encoding novel ROR1 binding partner is robust predictor of survival in chronic lymphocytic leukemia. HAEMATOLOGICA 103(2), p. 313 - 324, doi: 10.3324/haematol.2017.178699
• Kubesova, B; Pavlova, S; Malcikova, J; Kabathova, J; Radova, L; Tom, N; Tichy, B; Plevova, K; Kantorova, B; Fiedorova, K; Slavikova, M; Bystry, V; Kissova, J; Gisslinger, B; Gisslinger, H; Penka, M; Mayer, J; Kralovics, R; Pospisilova, S; Doubek, M, 2018: Low-burden TP53 mutations in chronic phase of myeloproliferative neoplasms: association with age, hydroxyurea administration, disease type and JAK2 mutational status. LEUKEMIA 32(2), p. 450 - 461, doi: 10.1038/leu.2017.230
• Tom, N; Tom, O; Malcikova, J; Pavlova, S; Kubesova, B; Rausch, T; Kolarik, M; Benes, V; Bystry, V; Pospisilova, S, 2018: ToTem: a tool for variant calling pipeline optimization. BMC BIOINFORMATICS 19, doi: 10.1186/s12859-018-2227-x

2017

• Plevova, K; Malcikova, J; Pavlova, S; Kotaskova, J; Poppova, L; Smardova, J; Diviskova, E; Durechova, K; Oltova, A; Brychtova, Y; Panovska, A; Doubek, M; Pospisilova, S, 2017: BIALLELIC TP53 GENE MUTATIONS DUE TO COPY-NEUTRAL LOSS OF HETEROZYGOSITY AND MONOALLELIC MUTATIONS IN ABSENCE OF 17P DELETION OCCUR IN CLL WITH COMPARABLE FREQUENCY. HAEMATOLOGICA 102, p. 65 - 66
• Kotaskova, J; Pavlova, S; Plevova, K; Malcikova, J; Stehlikova, O; Poppova, L; Kockova, H; Doubek, M; Bryja, V; Pospisilova, S, 2017: TREATMENT WITH BCR INHIBITORS INCREASES ROR1 EXPRESSION IN CLL CELLS. HAEMATOLOGICA 102, p. 414 - 414
• Malcikova, J; Kotaskova, J; Tom, N; Pal, K; Panovska, A; Brychtova, Y; Doubek, M; Pavlova, S; Pospisilova, S, 2017: Tracking low-burden TP53-mutated subclones during CLL treatment and remission using ROR1 separation. LEUKEMIA & LYMPHOMA 58, p. 162 - 163

2016

• Poppova, L; Janovska, P; Plevova, K; Radova, L; Plesingerova, H; Borsky, M; Kotaskova, J; Kantorova, B; Hlozkova, M; Figulova, J; Brychtova, Y; Machalova, M; Urik, M; Doubek, M; Kozubik, A; Pospisilova, S; Pavlova, S; Bryja, V, 2016: Decreased WNT3 expression in chronic lymphocytic leukaemia is a hallmark of disease progression and identifies patients with worse prognosis in the subgroup with mutated IGHV. BRITISH JOURNAL OF HAEMATOLOGY 175(5), p. 851 - 859, doi: 10.1111/bjh.14312
• Kubesova, B; Pavlova, S; Malcikova, J; Kabathova, J; Radova, L; Tom, N; Tichy, B; Plevova, K; Kantorova, B; Fiedorova, K; Kissova, J; Gisslinger, B; Gisslinger, H; Mayer, J; Kralovics, R; Pospisilova, S; Doubek, M, 2016: Low-Burden TP53 Mutations Occur in Chronic Phase of Myeloproliferative Neoplasms Regardless of Hydroxyurea Administration, Disease Type, and JAK2 Status. BLOOD 128(22)
• Janovska, P; Poppova, L; Plevova, K; Plesingerova, H; Behal, M; Kaucka, M; Ovesna, P; Hlozkova, M; Borsky, M; Stehlikova, O; Brychtova, Y; Doubek, M; Machalova, M; Baskar, S; Kozubik, A; Pospisilova, S; Pavlova, S; Bryja, V, 2016: Autocrine Signaling by Wnt-5a Deregulates Chemotaxis of Leukemic Cells and Predicts Clinical Outcome in Chronic Lymphocytic Leukemia. CLINICAL CANCER RESEARCH 22(2), p. 459 - 469, doi: 10.1158/1078-0432.CCR-15-0154
• Poppova, L; Janovska, P; Plevova, K; Radova, L; Plesingerova, H; Borsky, M; Kotaskova, J; Kantorova, B; Hlozkova, M; Figulova, J; Brychtova, Y; Doubek, M; Kozubik, A; Pospisilova, S; Pavlova, S; Bryja, V, 2016: DECREASED EXPRESSION OF WNT3, A CANONICAL WNT PATHWAY LIGAND, IS FREQUENT IN CHRONIC LYMPHOCYTIC LEUKEMIA PROGRESSION AND IDENTIFIES PATIENTS WITH SHORT TREATMENT-FREE SURVIVAL IN MUTATED IGHV SUBSET. HAEMATOLOGICA 101, p. 423 - 424
• Kotaskova, J; Pavlova, S; Greif, I; Stehlikova, O; Plevova, K; Janovska, P; Brychtova, Y; Doubek, M; Pospisilova, S; Bryja, V, 2016: ROR1-based immunomagnetic protocol allows efficient separation of CLL and healthy B cells. BRITISH JOURNAL OF HAEMATOLOGY 175(2), p. 339 - 342, doi: 10.1111/bjh.13848

2015

• Plesingerova, H; Janovska, P; Poppova, L; Shaik, A; Jurcickova, Z; Libra, A; Plevova, K; Machac, J; Slapak, I; Pavlova, S; Ovesna, P; Kotaskova, J; Doubek, M; Pospisilova, S; Bryja, V, 2015: UPREGULATED COBLL1 IN CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL) PATIENTS WITH UNMUTATED IGHV IDENTIFIES A COHORT WITH INFERIOR PROGNOSIS. HAEMATOLOGICA 100, p. 50 - 50
• Tom, N; Malcikova, J; Radova, L; Kantorova, B; Pardy, F; Pavlova, S; Pal, K; Mraz, M; Tichy, B; Doubek, M; Brychtova, Y; Plevova, K; Mayer, J; Trbusek, M; Pospisilova, S, 2015: MUTATIONS IN THE TP53 GENE SHOW FEATURES OF SOMATIC HYPERMUTATION PROCESS WITH PROMINENT DIFFERENCE BETWEEN IGHV MUTATED AND UNMUTATED CHRONIC LYMPHOCYTIC LEUKEMIA. HAEMATOLOGICA 100, p. 224 - 225
• Janovska, P; Poppova, L; Plesingerova, H; Plevova, K; Pavlova, S; Bryja, V, 2015: Wnt/planar cell polarity (PCP) and B cell receptor signaling in chronic lymphocytic leukemia. LEUKEMIA & LYMPHOMA 56, p. 63 - 64
• Kotaskova, J; Malcikova, J; Diviskova, E; Pavlova, S; Mejstrikova, S; Vranova, V; Plevova, K; Plesingerova, H; Doubek, M; Mayer, J; Pospisilova, S, 2015: 13Q DELETION IS PREDOMINANT CYTOGENETIC ABERRATION NEWLY AQUIRED DURING CHRONIC LYMPHOCYTIC LEUKEMIA COURSE IRRESPECTIVE OF DISEASE ACTIVITY AND TREATMENT STATUS. HAEMATOLOGICA 100, p. 417 - 418
• Kantorova, B; Malcikova, J; Smardova, J; Pavlova, S; Trbusek, M; Tom, N; Plevova, K; Tichy, B; Truong, S; Diviskova, E; Kotaskova, J; Oltova, A; Patten, N; Brychtova, Y; Doubek, M; Mayer, J; Pospisilova, S, 2015: TP53 mutation analysis in chronic lymphocytic leukemia: comparison of different detection methods. TUMOR BIOLOGY 36(5), p. 3371 - 3380, doi: 10.1007/s13277-014-2971-0
• Malcikova, J; Stano-Kozubik, K; Tichy, B; Kantorova, B; Pavlova, S; Tom, N; Radova, L; Smardova, J; Pardy, F; Doubek, M; Brychtova, Y; Mraz, M; Plevova, K; Diviskova, E; Oltova, A; Mayer, J; Pospisilova, S; Trbusek, M, 2015: Detailed analysis of therapy-driven clonal evolution of TP53 mutations in chronic lymphocytic leukemia. LEUKEMIA 29(4), p. 877 - 885, doi: 10.1038/leu.2014.297